Needham analyst Ami Fadia initiated coverage of Blueprint Medicines with a Buy rating and $60 price target. Ayvakit’s slowing growth in AdvSM is understood, and approval in non-AdvSM in 2023 should drive sales from ~$110M in 2022 to ~$1.3B in 2030, Fadia tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BPMC:
